Introduction {#Sec1}
============

HIV-infected individuals appear to be more vulnerable to sleep disturbances than the general population^[@CR1]--[@CR4]^. However, awareness of sleep disturbance as a health issue in general and as an HIV-related health issue specifically is low among patients, who do not emphasize such issues with their physician^[@CR5],\ [@CR6]^. Administration of standardized sleep assessment tools, such as the Pittsburg Sleep Quality Index (PSQI), Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), and the International Classification of Sleep Disorders (ICSD-2) in cohorts of HIV-infected individuals have observed a high prevalence of sleep disturbances from 40% to 70%^[@CR4],\ [@CR7],\ [@CR8]^. Major sleep disturbances frequently go undiagnosed and untreated and may have severe health consequences, such as depression and anxiety^[@CR6],\ [@CR9]^. A range of primary sleep disorder symptoms overlap with psychological and behavioral factors, requiring targeted diagnostic and treatment interventions^[@CR10],\ [@CR11]^.

The pathophysiology of sleeping disturbances among HIV-infected patients is unclear, but may be related to the ability of HIV to infect the central nervous system (CNS), the impact of antiretroviral medications, mental health issues, and substance abuse^[@CR6],\ [@CR12]--[@CR14]^. Sleep disturbances occur throughout all stages of infection, and may be associated with the virus itself, antiretroviral drugs, or antidepressants. It may also increase the risk for psychiatric disorders, cardiovascular morbidity, and mortality, but the degree and direction of causality are unclear^[@CR15],\ [@CR16]^.

Although the prevalence of sleeping disorders is reportedly high among HIV-infected persons, relatively few studies exist in the literature during the antiretroviral therapy (ART) era^[@CR15],\ [@CR17]^. Recent studies have largely focused on the impact of specific antiretroviral agents (e.g., efavirenz) on sleep disturbances^[@CR18]--[@CR20]^. Anxiety and depression are psychological factors that have been found to affect sleep quality^[@CR4],\ [@CR21],\ [@CR22]^. Regardless of its etiology, sleep disturbances is clinically important in this population due to potential impact on quality of life, adherence to ART cognition impairment, comorbid psychiatric disorders like anxiety/depression and immune system function^[@CR6],\ [@CR23],\ [@CR24]^. The purpose of this paper is to evaluate the epidemiology and associated risk factors for sleep disorders in AIDS patients and to recommend early evaluation for and detection of these conditions among people living with HIV.

Results {#Sec2}
=======

Characteristics of study population {#Sec3}
-----------------------------------

We evaluated 4103 HIV-infected persons (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}). Mean age of the cohort was 37.6 years (standard deviation \[SD\], 11.7 years), 79.4% were male, and 38.5% were MSM. The median time from HIV diagnosis to study enrollment was 27 months (interquartile range \[IQR\], 11--58 months), the median duration of ART was 18 months (IQR, 6--43 months), 15.5% had a current CD4+ cell count below 200 cells/mm3, and 48.4% had an undetectable HIV RNA level. 75.4% of patients were on their original first-line ART regimen and had not experienced an ART regimen switch.Table 1Demographic characteristics for all 4103 subjects \[n (%)\].CharacteristicsLevelsAge, years\<3030--50\>50Missing1175 (28.6%)2306 (56.2%)569 (13.9%)53 (1.3%)SexMaleFemaleMissing3204 (78.1%)831 (20.3%)68 (1.7%)Education\<High schoolHigh school\>High schoolMissing1528 (37.2%)988 (24.1%)1527 (37.2%)60 (1.5%)Transmission routeHeterosexualHomosexual/bisexualBlood transfusionPWIDOthers1589 (38.9%)1730 (42.2%)39 (1.0%)216 (5.3%)520 (12.7%)Marital statusMarriedDivorcedWidowedSingleMissing1698 (41.4%)456 (11.1%)132 (3.2%)1718 (41.9%)99 (2.4%)EmploymentWhite collarBlue collarUnemployedStudent1158 (28.2%)1835 (44.7%)280 (6.8%)830 (20.2%)Family history of mental illnessYesNoMissing85 (2.1%)4004 (97.6%)14 (0.3%)Personal history of mental illnessYesNoMissing65 (1.6%)4026 (98.1%)12 (0.3%)Current sleep medication useYesNo236 (5.8%)3867 (94.2%)Current antidepressant useYesNoMissing197 (4.8%)3884 (94.7%)22 (0.5%)HIV status disclosed to friendsYesNoMissing1092 (26.6%)2996 (73.0%)15 (0.4%)HIV status disclosed to familyYesNoMissing2464 (60.1%)1628 (38.7%)11 (0.3%)Support from family/friendsYesNoMissing2803 (68.3%)1239 (30.2%)61 (1.5%) Table 2Clinical characteristics for all 4103 subjects \[n (%)\].CharacteristicsLevelsCurrent CD4^+^ cell count, cells/mm^3^\<5050--200200--500≥500Missing128 (3.1%)506 (12.3%)2160 (52.6%)1272 (31.0%)37 (0.9%)Current viral loadUndetectableDetectableMissing1672 (40.8%)1781 (43.4%)650 (15.8%)Time since HIV diagnosis\<3 months≥3 monthsMissing297 (7.2%)374 (91.3%)58 (1.4%)Duration of ART\<1 year≥1 yearMissing1514 (36.9%)2528 (61.6%)61 (1.5%)Current EFV-based regimenYesNo2944 (71.8%)1159 (28.2%)Duration of EFV exposure0 month\<3 months≥3 monthsMissing1159 (28.2%)681 (16.6%)2217 (54.0%)46 (1.1%)Drug Adherence≥95%\<95%3642 (88.8%)461 (11.2%)Regimen switchingFirst-line ART regimenSwitched ART3093 (75.4%)1010 (24.6%)Current ART regimen pill burden3\>32438 (59.4%)1665 (40.6%)Number of ART Regimens01233067 (74.8%)726 (17.7%)233 (5.7%)77 (1.9%)

Prevalence of sleep disturbances {#Sec4}
--------------------------------

Median PSQI score for 3873 HIV-infected persons was 5 (IQR: 3--7). Over 40% (43.1%, 95% confidence interval \[CI\], 41.5%--44.7%) of participants had a PSQI score \>5, suggestive of sleep disturbance.

Prevalence of sleep disturbances among patients with anxiety and depression {#Sec5}
---------------------------------------------------------------------------

Median HADS score was 5 (IQR: 2--8) for anxiety and 5 (IQR: 2--9) for depression. Among the 3873 HIV-infected persons evaluated for anxiety and depression, prevalence of sleep disturbances differed significantly (P \< 0.001) between those who suffered anxiety (68.1%) and those who did not (33.6%), and between those who suffered depression (61.2%) and those who did not (34.3%).

Factors associated with sleep disturbances {#Sec6}
------------------------------------------

In univariate analyses, factors associated with sleep disturbance (PSQI \> 5) included age, education, transmission route, marital status, support from family/friends, time of diagnosed with HIV infection, drug adherence, number of ART regimens, current antidepressant use, and anxiety and depression. There were no significant associations with HIV-specific clinical factors including ART use (including EFV- containing regimens) and sleep. In the final multivariable model combining all of the significant variables above, factors associated with sleep disturbance based on the PSQI included education (P = 0.044), transmission route (P = 0.040), marital status (P \< 0.001), drug adherence (P = 0.001), current EFV-based regimen (P = 0.039), antidepressant use (P = 0.039), and anxiety and depression (P \< 0.001) (Table [3](#Tab3){ref-type="table"}).Table 3Demographic and clinical factors associated with sleep disturbances.Characteristics% of subjects with PSQI \> 5Univariate ModelMultivariable ModelOR (95% CI)P ValueOR (95% CI)P ValueDEMOGRAPHIC FACTORS Age, years0.035 \<3045.1%1.32 (1.07--1.63)0.010 30--5043.3%1.22 (1.01--1.49)0.041 \>5038.4%1 Gender0.633 Female42.3%1 Male43.3%1.04 (0.89--1.22) Education0.0030.046 \<High school39.6%11 High school44.3%1.22 (1.03--1.44)0.0221.22 (1.01--1.48)0.039 \>High school39.6%1.29 (1.11--1.49)0.0011.25 (1.03--1.53)0.025 Transmission route\<0.0010.050  Heterosexual37.5%11  Homosexual/bisexual46.5%1.45 (1.26--1.67)\<0.0011.26 (1.04--1.52)0.018  Blood transfusion40.0%1.11 (0.56--2.20)0.7610.99 (0.46--2.14)0.988  PWID53.7%1.93 (1.44--2.59)\<0.0011.40 (0.99--1.97)0.056  Others45.1%1.37 (1.12--1.69)0.0031.31 (1.04--1.65)0.024 Marital status\<0.0010.001  Married37.7%11  Divorced45.7%1.39 (1.12--1.73)0.0031.24 (0.98--1.58)0.074  Widowed46.3%1.42 (0.98--2.07)0.0621.53 (1.01--2.33)0.046  Single47.5%1.50 (1.30--1.72)\<0.0011.45 (1.21--1.74)\<0.001 Employment0.097  White collar43.7%1  Blue collar41.7%0.92 (0.79--1.07)0.284  Unemployed40.0%0.86 (0.65--1.13)0.273  Student46.5%1.12 (0.93--1.34)0.233 Support from family/friends\<0.001 Yes41.2%1 No47.5%1.29 (1.13--1.48)CLINICAL FACTORS Current CD4^+^ cell count, cells/mm30.870 \<5046.7%1.17 (0.81--1.71)0.402 50--19943.3%1.02 (0.83--1.2700.834200--49943.1%1.01 (0.88--1.17)0.864 ≥50042.8%1 Current viral load0.981  Undetectable43.1%1  Detectable44.5%1.00 (0.87--1.15) Time since HIV diagnosis0.035 \<3 months49.3%1.30 (1.02--1.67) ≥3 months42.7%1 Drug adherence\<0.0010.002 ≥95%42.0%11 \<95%52.2%1.51 (1.23--1.85)1.45 (1.14--1.83) Current EFV-based regimen0.331 Yes42.7%1 No44.4%1.07 (0.93--1.24) Duration of EFV exposure0.141 0 month44.4%1.12 (0.97--1.30)0.137 \<3 months45.4%1.17 (0.98--1.39)0.093 ≥3months41.6%1Duration of ART0.127 \<1 year44.7%1.11 (0.97--1.27) ≥1 year42.2%1 Number of ART Regimens0.0190.045 042.3%11 143.0%1.03 (0.87--1.21)0.7631.11 (0.92--1.35)0.278 249.6%1.34 (1.02--1.76)0.0361.27 (0.94--1.73)0.126 357.1%1.82 (1.12--2.93)0.0151.94 (1.12--3.35)0.018 Antidepressant use\<0.0010.044 Yes22.6%11.98 (1.47--2.67) No42.3%1.98 (1.47--2.67)1 Comorbidities\<0.001\<0.001 Anxiety \< 8 & Depression \< 830.7%11 Anxiety \< 8 & Depression ≥ 846.0%1.93 (1.59--2.33)\<0.0012.09 (1.70--2.57)\<0.001 Anxiety ≥ 8 & Depression \< 859.4%3.30 (2.60--4.18)\<0.0013.13 (2.44--4.00)\<0.001 Anxiety ≥ 8 & Depression ≥ 872.0%5.81 (4.86--6.98)\<0.0015.90 (4.86--7.16)\<0.001

Regarding the association of poor sleep and depression by Hospital Anxiety and Depression (HAD) scores, sleep disturbance was present in 34.3% of those without depression (P \< 0.001). Moreover, higher HAD scores were significantly associated with higher PSQI scores (r = 0.365; P \< 0.001). Participants with a higher risk of anxiety (HAD \> 8) had a 4-fold higher odds of sleep disturbance than those with lower HAD scores (HAD ≤ 8) (odds ratio \[OR\], 4.22; 95% CI, 3.63--4.91; P \< 0.001), whereas those with a higher risk of depression (HAD \> 8) had a 3-fold higher odds of sleep disturbance relative to those with a HAD ≤ 8 (OR, 3.01; 95% CI, 2.62--3.46; P \< 0.001).

Discussion {#Sec7}
==========

This study represents one of the largest epidemiologic studies of the prevalence of sleep disturbances as measured by PSQI among HIV-infected persons in the ART era^[@CR25],\ [@CR26]^. The PSQI is a standardized questionnaire frequently used in studies of HIV-positive persons, which has a cut-off score indicative of sleep disturbance, however, it lacks specificity for insomnia^[@CR11],\ [@CR27]--[@CR30]^.

HIV remains a highly stigmatized condition in China, with patients reporting emotional, financial, and physical burdens resulting from stigma^[@CR31]^. Discrimination is experienced from both medical and non-medical sources^[@CR31],\ [@CR32]^, despite legal protection from discrimination in accessing medical care, employment, and educational opportunities^[@CR33]^. The potential interaction between the experience of stigma and sleep disturbance have not been studied in this context but could potentially play a role in understanding sleep disturbance in this population.

Data from general population surveys in China suggest that the prevalence of sleep disturbance in healthy populations is about 10%^[@CR34]^. Our finding that HIV-infected persons have a high prevalence of sleep disturbance even in the ART era suggests that there are specific mechanisms causing poor sleep quality that are unique to this population or to HIV infection. HIV-infected persons with poor immune recovery did not have a statistically significantly higher rate of sleep disturbance when compared to those who had better immune recovery with nearly normal CD4^+^ cell counts above 500 cells/mm^3^. We did not find a relationship between sleep and CD4^+^ cell counts or HIV RNA in either direction. This is consistent with some studies that have not found any relationship^[@CR15],\ [@CR18]^, however others have found that sleep disturbances are independently related to immune status^[@CR26],\ [@CR35]--[@CR37]^. Other studies conducted in the pre-ART era showed an association between sleep and CD4^+^ cell counts or HIV RNA^[@CR7],\ [@CR38],\ [@CR39]^. The divergence of findings may be due to the differences in the tools used or to the fact that the prior studies were conducted in the pre-ART era when HIV perhaps played a more direct role in sleep.

Regarding HIV-specific factors, we found pill burden, poor adherence and more frequent switching of ART regimens were associated with higher proportions of poor sleep. These data suggest that in the ART era, patients with optimal adherence and patients who had not switched ART had lower rates of sleep disturbances. Duration of ART did not have statistical significance. Furthermore, patients on EFV-based regimen did not suffer a higher rate of sleep disturbance compared with patients on non-EFV-based regimens. However, patients who had initiated an EFV-based regimen in the last half year did have a marginally higher rate of sleep disturbance. This suggests that the sample may be biased, in that patients who had suffered CNS side effects from EFV may have switched regimens prior to the cross-sectional study, leaving only patients who did not suffer EFV-related side effects in the sample. In addition, antiretroviral agents with high CNS penetration effectiveness scores may be protective of HIV's effects on the CNS. On the other hand, some drugs may be associated with adverse sleep effects (e.g., EFV), especially at higher plasma levels^[@CR36],\ [@CR40],\ [@CR41]^. Data from prior studies among HIV-infected persons with EFV-based regimen did find much higher rates of sleep disturbance^[@CR40]^. However, these studies were conducted when patients had concurrent opportunistic infections^[@CR42]^, making attribution to EFV difficult. Our population consisted of all HIV-infected persons with free access to antiretroviral therapy, without AIDS-related opportunistic infections at the time of investigation.

In our study, the length of time since HIV diagnosis was found to be associated with sleep disturbances, with a significant association between shorter duration from diagnosis and poor quality of sleep. HIV infection remains a highly stigmatized illness in China, and can be accompanied by identity stigma and low self-esteem. These symptoms can be considered normal emotional responses to the reality of living with HIV as well as symptoms of depression. These may explain the higher rate of sleep disturbances in the first several months after diagnosis^[@CR7]^. This finding however conflicts with that of other studies that have assessed sleep disturbances in relation to duration of infection. Imeri and Opp and Seay *et al*. did not find any association between them in their studies^[@CR39],\ [@CR43]^.

In addition, HIV-infected women did not have a statistically significantly burden of sleep disturbance compared with men. People who used illicit drugs and MSM had a higher rate of sleep disturbances as compared to heterosexuals, which may be related to their marginalized position in Chinese society^[@CR44]^. Individuals with higher education had statistically greater odds of poor sleep compared with those with less education. Married individuals had a lower rate of sleep disturbance, potentially due to marriage conferring more family support, as we found that patients who report support from family or friends consistently had a lower rate of poor sleep.

The strongest associations found in our study were between depression and anxiety and sleep disturbance. This finding is consistent with other studies^[@CR21],\ [@CR45],\ [@CR46]^, and shows that psychiatric disorders are a major factor in sleep disturbances among HIV-infected patients. Given the likely bidirectional association between sleep and depression or anxiety, targeted management of one may improve the other. Therefore, treating depression and anxiety might improve sleep quality, and addressing sleep disturbances may relieve psychological morbidity^[@CR45],\ [@CR47],\ [@CR48]^.

Despite a high prevalence of sleep disturbance among HIV- infected persons, among patients with PSQI \> 5, only 11.19% were regularly using sleep medication. Treatment with cognitive behavioral therapy for sleep disturbance or insomnia, considered first line treatment for insomnia, was not measured. Prior studies have also noted that most patients with sleep disturbances remain untreated and often have a poor understanding of available treatment options^[@CR8],\ [@CR49]^.

Our study had several potential limitations. Sleep disturbances were diagnosed based on questionnaire data rather than polysomnograms or actigraphy data; however, we used standardized instruments comparable to those used in other studies, and some experts suggest that self-reported data may be more representative of sleep issues^[@CR4],\ [@CR27],\ [@CR50]^. The cross-sectional study design did not allow for assessment of the temporal relationship between poor sleep and factors (e.g., depression improvement or pre- and post-ART), the direction of causality, or for the assessment of whether sleep disturbances were transient or chronic in nature. Presence of pain, which has been shown to be associated with sleep disturbance in the literature, was not assessed. Finally, the lack of HIV-uninfected controls is a limitation of the study.

Our study had several strengths. This study is one of the largest study to date assessing sleep disturbance among HIV-infected patients on treatment^[@CR15],\ [@CR38],\ [@CR51]^. It used validated measures that are quick and inexpensive to implement to assess sleep disturbances, anxiety and depression and could easily be integrated into routine clinical practice^[@CR27],\ [@CR50]^.

In summary, the high prevalence of poor sleep suggests that treating sleep disturbances in those with HIV infection may have a positive impact on their quality of life and could potentially yield improvements to adherence to ARTs and mental health. HIV providers may consider routinely assessing sleep disturbances especially in the first three months of HIV diagnosis, and referring for mental health and social support services if PSQI \> 5. Therefore, integrating assessment of sleep disturbance into routine care and even extensive sleep quality evaluations at home for HIV-infected patients may be advisable in China. Prospective cohort studies that track sleep disturbance from time of diagnosis through treatment initiation and continuation could be useful to characterize the relationship between sleep disturbance, HIV, and treatment further.

Methods {#Sec8}
=======

Study Design and Participants {#Sec9}
-----------------------------

We conducted a cross-sectional study among 4724 HIV-infected adults on treatment, collecting data between January 2014 and December 2015 from patients at 20 HIV clinics across China covering Beijing, Guangxi, Yunnan *and other major municipalities*. The study enrolled patients accessing services at HIV clinics who were at least 18 years, diagnosed with HIV infection, on antiretroviral therapy, and not pregnant within the prior 3 months. Exclusion criteria included the presence of any acute medical condition that could affect the ability to complete the study questionnaire.

All participants provided written informed consent to complete a survey and have their medical data abstracted from their medical records. The study was approved by Beijing Youan Hospital institutional review board. All experiments were performed in accordance with relevant guidelines and regulations.

Main Outcomes {#Sec10}
-------------

Each participant completed the PSQI questionnaire, a 19-item questionnaire that assesses seven sleep components (sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of hypnotics, and daytime dysfunction) during the prior month. The scores for these components range from 0 (no difficulty) to 3 (severe difficulty) and are summed to produce a global measure of sleep disturbance, with a higher score denoting poorer sleep quality (range: 0--21). The Chinese version of PSQI was developed, widely used in adolescents, adults and elderly healthy and clinical groups, and showed good internal consistency, split half and retest reliability^[@CR52],\ [@CR53]^. We used the PSQI cut off of global score \>5 on the PSQI instrument^[@CR27]^ (sensitivity of 90% and specificity of 87%) to define sleep disturbance in this cohort. The HAD scale which consists of seven items relating to depression (HAD-D) and another seven relating to anxiety (HAD-A) was also administered and anxiety and depression were defined as a HAD score ≥8 on each subscale^[@CR54]^.

Demographic, behavioral, and psychosocial data were collected through self-administered survey. Clinical data were abstracted from medical records. This included HIV-specific data, like date of HIV diagnosis, history of medical conditions, current CD4^+^ cell counts and HIV RNA levels, and ART regimen at the time of survey. 4103 (86.9%) patients had complete data for analysis.

Statistical Analysis {#Sec11}
--------------------

Descriptive statistics are presented as means with SDs, or counts with proportions, as appropriate. Two sample t tests were used to compare means, and χ^2^ tests were used to compare proportions. Logistic regression analysis was used to investigate associations between sleep outcome and demographic, behavioral, psychosocial, and clinical factors. Odds ratios for sleep disturbance were estimated with 95% CIs. Factors with a P value \< 0.10 in univariate models were initially included in the multivariable model and were then eliminated using backward selection. Linear regression and the Pearson correlation coefficient were used to explore the relationship between the PSQI score and HAD score. All P values were 2-sided, and P values \< 0.05 were considered significant. Analyses were conducted using SPSS software 21.0.
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